

ANNEX

The following entries shall be added at the end of the table in Annex I to Directive 91/414/EEC:

No	Common name, identification numbers	IUPAC name	Purity ^a	Entry into force	Expiration of inclusion	Specific provisions
'149	Carbendazim (unstated stereochemistry) CAS No 10605-21-7 CIPAC No 263	Methyl benzimidazol-2- ylcarbamate	980 g/kg	1 January 2007	31 December 2009	PART A Only uses as fungicide on the following crops may be authorised: — cereals — rapeseed — sugar beet — maize at rates not exceeding — 0,25 kg active substance per hectare per application for cereals and rapeseed, — 0,075 kg active substance per hectare per application for sugar beet, — 0,1 kg

^a Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						<p>active substance per hectare per application for maize.</p> <p>The following uses must not be authorised:</p> <ul style="list-style-type: none"> — air application, knapsack and hand-held applications neither by amateur nor by professional users, home gardening. <p>Member States shall ensure that all appropriate risk mitigation measures are applied. Particular attention must be paid to the protection of:</p> <ul style="list-style-type: none"> — aquatic organisms. An appropriate distance must be kept
a	Further details on identity and specification of active substance are provided in the review report.					

							between treated areas and surface water bodies. This distance may depend on the application or not of drift reducing techniques or devices, earthworms and other soil macro-organisms. Conditions of authorisation shall include risk mitigation measures, such as the selection of the most appropriate combination of numbers and timing of application, rates
--	--	--	--	--	--	--	--

a Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						of application, and, if necessary, the degree of concentration of the active substance, birds and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that
--	--	--	--	--	--	---

a Further details on identity and specification of active substance are provided in the review report.

							ensure an adequate avoidance, minimise the exposure of the concerned species, operators, who must wear suitable protective clothing, in particular gloves, coveralls, rubber boots and face protection or safety glasses during mixing, loading, application and cleaning of the equipment, unless the exposure to the substance is adequately precluded by the design and
--	--	--	--	--	--	--	--

a Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After
IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

construction
of
the
equipment
itself
or
by
the
mounting
of
specific
protective
components
on
such
equipment.

PART B For
the
implementation
of
the
uniform
principles
of
Annex
VI,
the
conclusions
of
the
review
report
on
carbendazim,
and
in
particular
Appendices
I
and
II
thereof,
shall
be
taken
into
account.

Member
States must
ensure
that the

a Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					authorisation holders report at the latest on 31 December of each year on incidences of operator health problems. Member States may require that elements, such as sales data and a survey of use patterns, are provided so that a realistic picture of the use conditions and the possible toxicological impact of carbendazim can be obtained.’
--	--	--	--	--	---

a Further details on identity and specification of active substance are provided in the review report.
